Vaccination News Home Page

http://bmj.com/cgi/content/full/325/7356/120/b

PDF of this article Email this article to a friend Respond to this article PubMed citation Related articles in PubMed Download to Citation Manager Search Medline for articles by: Spurgeon, D. Alert me when: New articles cite this article

Collections under which this article appears: Other Infectious Diseases Cancer:other

BMJ 2002;325:120 ( 20 July )

News

Chickenpox vaccine may reduce risk of shingles

David Spurgeon, Quebec

Stanford University researchers have found that giving an inactivated form of chickenpox vaccine to adults can reduce the risk of herpes zoster (shingles), which strikes elderly people and people with weakened immune systems.

Even among healthy adults the risk of shingles rises each decade after age 60, increasing to one in five people in their 80s. Patients who have had a transplantation are at high risk of the condition, because their immune system is impaired.

Shingles is triggered by the same virus that causes chickenpox. Once someone is infected by the virus, it remains latent in nerve cells and can be reactivated when the immune system is weakened. It causes an itchy, burning rash and shooting pains that can last for years.

Dr Ann Arvin, chief of paediatric infectious diseases at Lucille Packard Children's Hospital and a professor of microbiology and immunology in Stanford University's medical school, and colleagues decided to see whether inactivated chickenpox vaccine could protect patients with cancer who received haemopoietic cell transplants against such reactivation. They used a heat inactivated preparation of the childhood vaccine, made for purposes of investigation by Merck and not available commercially.

Reporting in the New England Journal of Medicine (2002; 347:26-34), the researchers said that seven of 53 patients who received one dose of the inactivated vaccine within 30 days before the transplantation, followed by three doses after the transplantation, developed shingles, compared with 17 of the 56 participants in the unvaccinated control group.

The researchers believe that administration of inactivated vaccine could benefit other people at risk of shingles and that the strategy of vaccination before transplantation could protect other patients against other viruses and bacteria.

© BMJ 2002
 

PDF of this article Email this article to a friend Respond to this article PubMed citation Related articles in PubMed Download to Citation Manager Search Medline for articles by: Spurgeon, D. Alert me when: New articles cite this article

Collections under which this article appears: Other Infectious Diseases Cancer:other

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.